For many reasons, 2020 was a transformational year for Circassia as the new management team set to work streamlining the business, addressing legacy issues and positioning the group to benefit from the strong market position of NIOX, a gold standard diagnostic device for asthma. Whilst the pandemic has had an impact, recovery is underway, with Q4 revenues back to 86% of Q1 levels. The EBITDA breakeven point of the business has been reduced further to £32.0m and there was £7.4m of net cash on the ....
12 Jan 2021
Full year trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Full year trading update
NIOX Group Plc (NIOX:LON) | 64.2 0 0.0% | Mkt Cap: 271.4m
- Published:
12 Jan 2021 -
Author:
Chris Glasper -
Pages:
3
For many reasons, 2020 was a transformational year for Circassia as the new management team set to work streamlining the business, addressing legacy issues and positioning the group to benefit from the strong market position of NIOX, a gold standard diagnostic device for asthma. Whilst the pandemic has had an impact, recovery is underway, with Q4 revenues back to 86% of Q1 levels. The EBITDA breakeven point of the business has been reduced further to £32.0m and there was £7.4m of net cash on the ....